continuum steering committee

Philip AshersonProfessor Philip Asherson

Professor of Molecular Psychiatry, Genetic and Developmental Psychiatry Research Centre, King’s College London, UK

Professor Philip Asherson has been a Lead Clinician in the National Adult ADHD Clinic at the Maudsley Hospital, London, UK, since 1998. His research focuses on clinical, quantitative genetic and molecular genetic studies of ADHD in adults and in children, and the clinical assessment and treatment of ADHD in adults. He was a member of the National Institute of Health and Clinical Excellence (NICE) Guideline Development Group for ADHD across the lifespan and is the president of the UK Adult ADHD Network – a national network for the support of clinicians diagnosing and treating ADHD in the UK. Professor Asherson has authored over 270 peer-reviewed articles and book chapters on ADHD and other psychiatric conditions, including two books on ADHD in adults.

Disclosures: Professor Asherson has acted as a consultant for Shire, Lilly, Janssen and Novartis on behalf of King’s College London. On behalf of King’s College London, he has received educational or research grants from Shire, Lilly, Janssen, Vifor Pharma and Qbtech, and presented at educational events organised or sponsored by these companies.

scroll to top

Celso ArangoProfessor Celso Arango

Head of the Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, CIBERSAM, Madrid, Spain

Associate Professor of Psychiatry, Maryland Psychiatric Research Center, University of Maryland, Baltimore MN, USA

Professor Arango is the Scientific Director of the Spanish Psychiatric Research Network. He is the author of 6 books, more than 35 book chapters and over 230 peer-reviewed articles, including 6 on ADHD. Professor Arango holds 19 awards conferred by Spanish and international scientific societies, as well as the Cross of Civil Merit in Health.

Disclosures: Professor Arango has been a consultant to or has received honoraria or grants from Abbott, Astra Zeneca, Bristol-Myers Squibb, Caja Navarra, CIBERSAM, Fundación Alicia Koplowitz, Instituto de Salud Carlos III, Janssen Cilag, Lundbeck, Merck, Ministerio de Ciencia e Innovación, Ministerio de Sanidad, Ministerio de Economía y Competitividad, Mutua Madrileña, Otsuka, Pfizer, Roche, Servier and Schering Plough.

scroll to top

Professor Dr Dr Tobias BanaschewskiProfessor Dr Dr Tobias Banaschewski

Professor of Child and Adolescent Psychiatry at the Medical Faculty Mannheim of the University of Heidelberg, Germany

Medical Director of the Department of Child and Adolescent Psychiatry of the Central Institute of Mental Health in Mannheim, Germany

Professor Dr Dr Banaschewski obtained his psychology and medicine degree at the University of Marburg in Germany. He worked as Clinical Assistant in Adult Psychiatry in Marburg and as Clinical and Research Assistant in Child and Adolescent Psychiatry at the University of Göttingen. Professor Dr Dr Banaschewski’s research focuses on ADHD and comorbid disorders and he is the author of over 165 original papers and review articles, and 27 book chapters. In 2003 he was awarded the Kramer-Pollnow Award in recognition of his contribution to ADHD research. He is a member of numerous organisations and societies including the Executive Committee of the German Society of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy (DGKJP), and a board committee member of the German ADHD network. Professor Banaschewski also acts as a board member and reviewer for several academic journals.

Disclosures: Professor Dr Dr Banaschewski served in an advisory or consultancy role for Bristol Myers-Sqibb, Develco Pharma, Lilly, Medice, Novartis, Shire and Viforpharma. He received conference attendance support and conference support or received speakers’ fee from Lilly, Janssen McNeil, Medice, Novartis and Shire. He is/has been involved in clinical trials conducted by Lilly and Shire. His present work with Continuum is unrelated to the above grants and relationships.

scroll to top

Maite FerrinDr Maite Ferrin

Consultant Psychiatrist, Huntercombe Hospital, Maidenhead, UK

Honorary Research Associate, Department of Child and Adolescent Psychiatry, Institute of Psychiatry London, UK

Dr Maite Ferrin obtained her medical degree at the University of Navarra, Spain, before completing her MSc and PhD research at King’s College London and the University of Granada.
Dr Ferrin has been a full-time Consultant Psychiatrist since 2006, working in Jaen and Navarra, Spain, specialising in child and adolescent psychiatry. She has lead psychoeducation projects for families of ADHD patients in both Spain and London and has sat on the European ADHD Guidelines Group (EAGG, Eunethydis) since 2010. In addition, Dr Ferrin has contributed to the J-Eunethydis organising committee as well as several Spanish groups working to improve ADHD treatment (GEITADH, GEIDA). Dr Ferrin is also active in ADHD research, with a number of peer-reviewed publications to her name. She is a peer reviewer for several international child and adolescent psychiatry journals and Deputy Editor of the IACAPAP (International Association for Child and Adolescent Psychiatry and Allied Professions) bulletin.

Disclosures: Dr Ferrin has received economic support from the Instituto de Salud Carlos III (ETS 07/90902, BAE 09/90088), Consejeria de Salud Junta de Andalucıa (EF-0029) Fundacion Alicia Koplowitz and Gobierno de Navarra (Beca Ayanz). She declares no other conflict of interest.

scroll to top

Dr Mats Johnson

Chief Physician, Child Neuropsychiatry Unit, Queen Silvia’s Hospital for Children, Gothenburg, Sweden

Researcher, Gillberg Neuropsychiatry Centre, Sahlgrenska Academy, University of Gothenburg

Dr Mats Johnson is a Chief Physician, overseeing the assessment and treatment of neuropsychiatric disorders in children and adolescents at Queen Silvia’s Hospital, Gothenburg, Sweden. In his capacity as a researcher, Dr Johnson is based at the Gillberg Child Neuropsychiatry Centre, University of Gothenburg, and his research focuses on interventions for ADHD, oppositional defiant disorder, neurodevelopmental disorders, challenging behaviours, and conduct disorder in children and adolescents. He has a number of peer-reviewed articles to his credit and has recently been awarded his PhD.

Disclosures: Dr Johnson has received research support from Equazen/Vifor Pharma, Shire, The Wilhelm and Martina Lundgrens Foundation and the Swedish MRC. Funders have had no involvement in study design, data collection or analysis, manuscript preparation or publication decisions. He has received honoraria as a speaker and advisory board member from Lilly, Janssen, Novartis, Shire and Vifor Pharma.

scroll to top